Drawing upon a unique combination of expertise and state-of-the-art methods and tools in
neurobiology, epidemiology, clinical science, environmental science and data science, the ADAIR consortium is uniquely placed to, for the first time, provide crucial mechanistic insight about the effects of air pollutants on the brain in humans and discover biomarkers for air pollution and AD risk prediction. ADAIR applies a precision medicine approach to stratify individuals to subgroups
for risk estimation and future AD prevention, ultimately aiming to target air pollution induced effects
in those individuals that can most benefit from them. The project investigates the novel, ambitious
hypothesis that the pollutant exposure environment of an individual alters cellular mechanisms
and functions, resulting in the expression of measurable biomarkers. By identifying biomarkers,
the individuals with increased AD risk can be stratified prior to the disease onset and preventive measures can be targeted to the specific at-risk populations in order to be most effective.